Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
$16.26
-10.9%
$13.27
$7.80
$28.09
$887.96MN/A591,153 shs2.41 million shs
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$34.85
+2.7%
$36.28
$23.23
$39.95
$1.10B0.65375,114 shs370,321 shs
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$14.07
+0.5%
$14.06
$7.31
$17.08
$963.59M0.047,672 shs9,954 shs
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
$3.71
-5.4%
$2.90
$0.78
$4.11
$264.56M1.011.31 million shs1.07 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
0.00%+2.64%+74.81%+62.37%-16.89%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
0.00%+5.93%-5.06%+9.80%-11.71%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.00%-0.24%-5.91%+38.01%+52.82%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
0.00%+10.11%+70.43%+32.88%+54.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
$16.26
-10.9%
$13.27
$7.80
$28.09
$887.96MN/A591,153 shs2.41 million shs
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$34.85
+2.7%
$36.28
$23.23
$39.95
$1.10B0.65375,114 shs370,321 shs
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$14.07
+0.5%
$14.06
$7.31
$17.08
$963.59M0.047,672 shs9,954 shs
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
$3.71
-5.4%
$2.90
$0.78
$4.11
$264.56M1.011.31 million shs1.07 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
0.00%+2.64%+74.81%+62.37%-16.89%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
0.00%+5.93%-5.06%+9.80%-11.71%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.00%-0.24%-5.91%+38.01%+52.82%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
0.00%+10.11%+70.43%+32.88%+54.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
2.75
Moderate Buy$31.8695.93% Upside
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3.00
Buy$42.3321.47% Upside
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.40
Hold$30.00113.30% Upside
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
2.00
Hold$7.50102.16% Upside

Current Analyst Ratings Breakdown

Latest VTYX, COLL, PHAR, and BCAX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/14/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
10/8/2025
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
10/8/2025
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/30/2025
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
9/27/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
9/27/2025
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
9/27/2025
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/24/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
8/22/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$41.00 ➝ $40.00
(Data available from 10/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/A$9.04 per shareN/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$631.45M1.74$12.67 per share2.75$7.10 per share4.91
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$297.20M3.24$0.07 per share188.86$3.25 per share4.33
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/AN/AN/AN/A$3.59 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$68M-$3.17N/AN/AN/AN/A-21.67%-20.89%11/11/2025 (Estimated)
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$69.19M$1.0433.515.79N/A5.13%97.28%13.87%11/6/2025 (Estimated)
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$11.84M-$0.13N/A468.83N/A-2.19%-3.31%-1.78%10/23/2025 (Estimated)
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
-$135.12M-$1.68N/AN/AN/AN/A-48.89%-44.87%11/6/2025 (Estimated)

Latest VTYX, COLL, PHAR, and BCAX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/11/2025Q3 2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$0.55N/AN/AN/AN/AN/A
11/6/2025Q3 2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.89N/AN/AN/A$191.25 millionN/A
11/6/2025Q3 2025
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$0.05N/AN/AN/AN/AN/A
11/6/2025Q3 2025
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
-$0.44N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$0.54-$0.50+$0.04-$0.50N/AN/A
8/7/2025Q2 2025
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
-$0.45-$0.38+$0.07-$0.38N/AN/A
7/31/2025Q2 2025
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$0.10$0.06+$0.16$0.06$70.36 million$93.20 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/AN/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/AN/AN/AN/AN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
N/AN/AN/AN/AN/A
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
25.80
25.80
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3.27
1.18
1.10
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.38
2.79
2.07
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/A
19.12
19.12

Institutional Ownership

CompanyInstitutional Ownership
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.03%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
97.88%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3254.61 millionN/AN/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
21031.50 million30.71 millionOptionable
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
28068.51 million67.10 millionNot Optionable
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
3071.31 million58.35 millionOptionable

Recent News About These Companies

Ventyx (VTYX) Q2 Net Loss Drops 16%
VTYX - Ventyx Biosciences Inc News - Morningstar
VTYX - Ventyx Biosciences Inc Financials - Morningstar

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bicara Therapeutics stock logo

Bicara Therapeutics NASDAQ:BCAX

$16.26 -1.99 (-10.90%)
Closing price 04:00 PM Eastern
Extended Trading
$16.22 -0.05 (-0.28%)
As of 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Collegium Pharmaceutical stock logo

Collegium Pharmaceutical NASDAQ:COLL

$34.85 +0.91 (+2.68%)
Closing price 04:00 PM Eastern
Extended Trading
$34.84 -0.01 (-0.01%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Pharming Group stock logo

Pharming Group NASDAQ:PHAR

$14.06 +0.07 (+0.46%)
Closing price 03:57 PM Eastern
Extended Trading
$13.66 -0.40 (-2.88%)
As of 05:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Ventyx Biosciences stock logo

Ventyx Biosciences NASDAQ:VTYX

$3.71 -0.21 (-5.36%)
Closing price 04:00 PM Eastern
Extended Trading
$3.75 +0.04 (+1.11%)
As of 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.